Sanofi-Aventis has received an approvable letter from the FDA’s Division of Metabolism and Endocrinology Products for rimonabant for weight management, and a non-approvable letter from the Division of Anesthesia, Analgesia and Rheumathology Products, for smoking cessation. Sanofi-Aventis will continue to work closely with the FDA. Rimonabant is the first in a new class of therapeutic agents called CB(1) blockers.